ESMO Open
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
ESMO Open
Jul 11, 2024, 14:28 |
Blog
Alice Avancini: Exercise promotion in cancer by the oncologists
Kathryn Schmitz, Oncology researcher at Pitt’s School of Medicine and the director of UPMC Hillman’s…
Jul 4, 2024, 14:15 |
Insight
Evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment
ESMO Open shared a post on X: "Hot off the press: Francesco Schettini et al.…
Jul 2, 2024, 15:04 |
Blog
Francesco Schettini: Molecular changes induced by neoadjuvant CT and ET in breast cancer
Francesco Schettini, Medical Oncologist at the Breast Unit of the Hospital Clinic of Barcelona and Postdoc…
Jun 26, 2024, 15:13 |
Blog
Toni Choueiri: Our new IMDC paper in ESMO Open led by Kosuke Takemura
Toni Choueiri shared a post by Kosuke Takemura, Staff Urologist at Ganken Hospital, on X: "Our new…
Jun 23, 2024, 11:13 |
Blog
The new Impact Factor for ESMO Open has just been released
ESMO Open shared on X: "The new Impact Factor for ESMO Open has just been…
Jun 19, 2024, 12:19 |
Blog
Oncology Advance - See this month’s highlights from the ESMO portfolio
Oncology Advance shared a post on X: "See this month’s highlights from the ESMO portfolio. Featured…
Jun 15, 2024, 16:02 |
Dialogues
Oncodaily Talks: Dialogue with Giuseppe Curigliano, hosted by Chandler Park
OncoDaily Talks gathers people worldwide to discuss challenges in cancer care. We share creative solutions…
Jun 14, 2024, 16:10 |
Insight
Ghassan Abou-Alfa on a paper by Arndt Vogel et al.
Ghassan Abou-Alfa, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on…
Jun 10, 2024, 10:08 |
Societies
Vivek Subbiah: I endorse Dr. Giuseppe Curigliano for ESMO President 2027-28
Vivek Subbiah shared on X: "The elections for the ESMO President 2027-2028 are happening, its…
Jun 9, 2024, 01:38 |
Insight
Stephen V Liu reflects on OS from PACIFIC-R
Stephen V Liu shared the following insight on X: "OS from PACIFIC-R: real-world outcomes with…
Jun 7, 2024, 11:07 |
Blog
Paolo Tarantino: Grateful to be part of the ESMO Open team
Paolo Tarantino shared a post by Giuseppe Curigliano on LinkedIn: "Grateful to be part of the…
May 25, 2024, 07:41 |
Insight
Paolo Tarantino: I’m extremely excited to support Giuseppe Curigliano for the next ESMO Presidential Elections!
Paolo Tarantino shared on LinkedIn: “I’m extremely excited to support Giuseppe Curigliano for the next…
May 24, 2024, 00:42 |
Societies
Vivek Subbiah wholeheartedly supports and endorses Dr. Giuseppe Curigliano for ESMO President 2027-28
Vivek Subbiah shared on X: "Exciting news! The elections for the ESMO President 2027-2028 are…
May 23, 2024, 14:29 |
Societies
The names of the candidates running for the ESMO Presidency 2027-2028 have been announced
The names of the candidates running for the ESMO Presidency 2027-2028 have been announced. Find…
May 15, 2024, 04:35 |
Blog
Paolo Tarantino: A pleasure to co-host the latest ESMO Open podcast with Giuseppe Curigliano
Paolo Tarantino shared a post by ESMO - European Society for Medical Oncology on LinkedIn, adding:…
May 7, 2024, 06:28 |
Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
May 6, 2024, 13:19 |
Blog
Jon Lim: Some real challenges faced by oncologists in pursuing postgrad degrees
Jon Lim, Medical Oncologist and Postdoctoral Clinical Fellow at The Francis Crick Institute, posted on…
Apr 28, 2024, 16:53 |
Blog
Paolo Tarantino: Unmissable editorial on the current status and next steps for studying and treating brain metastases in breast oncology
Paolo Tarantino shared a post by ESMO Open, on X: "Unmissable editorial on the current status…
Apr 28, 2024, 12:38 |
Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 25, 2024, 00:51 |
Insight
New Paper Alert! Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma Authors: T. Powles,…
Apr 19, 2024, 06:47 |
Positive
Editor Spotlight this week is Susana Banerjee - ESMO Open
ESMO Open shared on X: “Our Editor Spotlight this week is Susana Banerjee, ESMO Open…
Apr 17, 2024, 13:11 |
Insight
New Paper Alert! Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal Cancer: A Real-World Analysis
New Paper Alert: Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal…
Apr 16, 2024, 00:17 |
Blog
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn: "In our latest…
Apr 11, 2024, 17:37 |
Societies
Our Editor Spotlight this week is John B. Haanen, editor for immunotherapy - ESMO Open
ESMO Open shared a post on X: “Our Editor Spotlight this week is John B.…
Mar 31, 2024, 14:36 |
Insight
Nazik Hammad: First systematic review on cancer workforce
Nazik Hammad posted on LinkedIn: "1st systematic review on cancer workforce. 1st lesson: quantity is not…
Mar 23, 2024, 14:45 |
Insight
Article summaries by Erman Akkus: BMI and cancer prognosis and billiary tract cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X/Twitter: 1. ''BMI, weight…
Mar 21, 2024, 10:54 |
Insight
The Swedish SCAN-B cohort, the HER2DX risk-score was found significantly associated with OS after adjustment for clinical variables and treatment regimen - ESMO Open
ESMO Open posted on X: "Hot off the press: among 757 patients with early HER2+ breast…
Mar 13, 2024, 23:46 |
Blog
Guilherme Nader Marta: Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn: “Our meta-analysis looking…
Mar 8, 2024, 19:21 |
Societies
Our Editor Spotlight this week is Chiara Cremolini - ESMO Open
ESMO Open Journal announced on their X/Twitter page: "Our Editor Spotlight this week is Chiara…
Feb 26, 2024, 10:49 |
Blog
Our Editor Spotlight this week is Solange Peters - ESMO Open
The Open Access journal of ESMO shared on their X/Twitter: ''Our Editor Spotlight this week is…
Feb 8, 2024, 17:54 |
Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Nov 19, 2023, 00:17 |
Blog
Stephanie Graff: Another brilliant editor-in-chief announcement from The European Society for Medical Oncology, this time for ESMO Open
Stephanie Graff shared the following on Twitter: “Another brilliant editor-in-chief announcement from The European Society…
Nov 11, 2023, 12:49 |
Blog
Benedikt Westphalen: CUPISCO is out in ESMO Open
Benedikt Westphalen, Medical Lead of Precision Oncology at the Cancer Center Munich, shared on LinkedIn:…
Sep 7, 2023, 19:38 |
Insight
Jarushka Naidoo: The secret to a long life as a clinician scientist is the same as a long marriage.
Quoting Jarushka Naidoo, a Professor of Medical Oncology at the Royal College of Surgeons in Ireland…
All:
34
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube